Crinetics Pharmaceuticals Approves Merger with Vertex; Closing ~Sep 1, 2026

What Happened
Crinetics Pharmaceuticals (CRNX) reported that its special meeting of shareholders approved the Agreement and Plan of Merger with Vertex Pharmaceuticals and Clark Merger Sub, Inc. A total of 79,264,631 shares (74.71% of outstanding shares) were represented at the meeting (record date July 27, 2026). The Merger Proposal received 79,240,098 votes for, 13,618 against and 10,915 abstentions. The company said this shareholder approval satisfies the final outstanding condition to closing and anticipates the Merger will close on or about September 1, 2026.

Key Details

• Meeting turnout: 79,264,631 of 106,095,205 outstanding shares (74.71%) — quorum present.
• Merger vote (Proposal 1): For 79,240,098; Against 13,618; Abstained 10,915.
• Advisory compensation vote (Proposal 2) failed: For 33,854,149; Against 44,803,403; Abstained 607,079. This vote was non‑binding and not a condition to closing.
• Proposal 3 (adjournment) was not needed because sufficient votes existed to approve the Merger.

Why It Matters
Shareholder approval clears the final stated condition for the transaction, making the closing likely imminent — Crinetics will become a wholly owned subsidiary of Vertex upon closing. The failed advisory vote on transaction‑related executive compensation signals shareholder disapproval of the disclosed pay arrangements, though it does not block the Merger. The 8‑K also includes standard forward‑looking statements and notes that closing remains subject to usual risks and conditions (e.g., termination rights, regulatory approvals, and other closing conditions). Investors should watch for the official closing notice and any post‑closing integration updates.